FDA complete response letters: what they mean for peptide-drug approval

01

A complete response letter is an application action, not approval

FDA's complete-response framework replaced the older approvable and not-approvable letter system for human drug marketing applications. FDA says a CRL indicates that the review cycle is complete and that the application is not ready for approval. It does not authorize marketing of the product for the proposed use.

The action belongs to a particular New Drug Application, Abbreviated New Drug Application, or Biologics License Application and the material reviewed in that cycle. It should not be generalized to every formulation, indication, sponsor, or molecule that shares an ingredient name.

For a peptide candidate, record the sponsor, application number, product name, formulation, route, proposed indication, action date, and exact source. A headline saying 'FDA rejected the peptide' may conceal whether the action concerned a manufacturing site, one indication, a specific combination, or the adequacy of the submitted evidence.

02

What deficiencies a CRL may describe

FDA's 2025 transparency announcement says CRLs may involve safety and effectiveness concerns, manufacturing deficiencies, and bioequivalence issues. Other application problems can include inspections, product quality, proposed labeling, study conduct, statistical analysis, or information needed to complete a benefit-risk evaluation.

The existence of a manufacturing deficiency does not establish that the clinical data were favorable, and a clinical deficiency does not show that every manufacturing issue was resolved. Read the letter by discipline and avoid turning one disclosed item into an exhaustive explanation unless FDA says it is complete.

A CRL also is not a product recall. A recall addresses a marketed product or lot, while a CRL addresses whether an application can be approved in its current form. It is not a clinical hold, which concerns whether an investigational study may proceed, and it is not withdrawal of an already approved indication.

03

What can happen after the letter

A sponsor can prepare a complete resubmission that addresses the deficiencies, request a meeting, pursue available dispute mechanisms, amend its program, withdraw the application, or stop development. FDA begins a new review cycle only after the applicable response is accepted as complete under the relevant framework.

The time and evidence needed vary. Some issues may be addressed with manufacturing documentation or labeling changes; others may require inspections, analyses, stability information, bioequivalence work, or an additional clinical trial. A company statement that it expects a quick resubmission is a plan, not an FDA finding that the issue is minor.

Later approval is possible but not guaranteed. FDA's public database contains letters associated with both applications that were later approved and applications that remained unapproved. When status changes, report both the earlier CRL and the later approval with dates rather than erasing the history or treating the first action as permanent.

04

What the public can—and cannot—see

FDA historically treated many pending-application details as confidential. The agency began publishing large sets of redacted CRLs and now offers a searchable openFDA resource. FDA says the database includes letters connected to approved and unapproved NDAs and BLAs and that it will continue adding material.

The database is not a complete real-time log of every current application action. FDA notes that letters can contain confidential commercial and trade-secret information that must be redacted. The public dataset also describes its update frequency as infrequent and the displayed time coverage may lag the newest agency actions.

A no-result search therefore cannot prove that FDA did not issue a CRL. Use the application number, sponsor name, product, and letter date when searching, then review Drugs@FDA, company securities filings, official releases, and later labels. Attribute sponsor-only details to the sponsor and label any undisclosed rationale as unknown.

05

A verification workflow for a peptide CRL claim

Capture the original claim before it changes. Determine whether it says FDA issued a CRL, refused to file an application, placed a trial on hold, extended a review goal, or denied a citizen petition. Those actions answer different questions and should not be grouped under the word rejection.

Search FDA's CRL table and API documentation, then search Drugs@FDA for the exact application. If a company release is the only current source, compare it with an SEC filing and preserve its stated limitations. Look for whether the company identifies clinical, safety, manufacturing, inspection, labeling, or other categories and whether it plans to resubmit.

After any claimed resubmission or new goal date, continue to check for an approval letter and current label. A restarted review, accepted resubmission, PDUFA goal, Fast Track status, or clinical-trial record still does not equal approval. Only the approval action authorizes the specific marketing application.

• →Exact sponsor and product
• →NDA, ANDA, or BLA number
• →Proposed indication
• →CRL action date
• →FDA versus sponsor disclosure
• →Deficiency categories actually stated
• →Later resubmission and approval records

06

Marketing warning signs and interpretation limits

Warning signs include describing a CRL as a temporary paperwork delay without evidence, claiming FDA endorsed the drug but requested one small change, announcing a guaranteed approval date, or using continued study activity to imply that the marketing application passed review.

The opposite overstatement is also misleading. A CRL does not necessarily establish that a molecule can never be approved, that every studied use failed, or that an unrelated marketed product is unsafe. Report the exact scope and leave undisclosed information unknown.

An application decision does not answer whether another approved drug is suitable for a patient and does not justify buying an unapproved research or compounded substitute. Treatment decisions belong with an appropriately licensed clinician using current labels and evidence. This guide does not predict FDA outcomes or recommend any product.